Clinical Trial Update: Phase 2 Study to Assess the Safety and Efficacy of ANG003 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial to evaluate the safety and efficacy of ANG003 for exocrine pancreatic insufficiency and cystic fibrosis. The study status is NOT_YET_RECR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• ANG003

Snippet

Sponsor: Anagram Therapeutics, Inc. | Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Status: NOT_YET_RECRUITING